{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:04:42Z","timestamp":1789704282672,"version":"4.0.1"},"reference-count":45,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T00:00:00Z","timestamp":1590192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Treatment\u2010free remission (TFR), in which patients discontinue pharmacotherapy and remain in molecular remission, is an emerging treatment goal for patients with chronic myeloid leukemia (CML). Attainment of TFR requires an increased frequency of molecular monitoring, to ensure that patients maintain a deep molecular response. The objective of this analysis was to assess the economic impact of stopping nilotinib among Japanese TFR\u2010eligible patients. A Markov model evaluated the economic impact of TFR among the study population, TFR\u2010eligible CML patients diagnosed since 2012. The model compared patients who had discontinued tyrosine kinase inhibitor (TKI) treatment (ie, attempted TFR) with patients that continued TKI treatment. A 3\u2010y time horizon was modeled from a Japanese public payer perspective. Costs associated with drug treatment, hospital\/physician visits, and molecular monitoring were considered. TFR\u2010eligible patients were calculated from Japanese CML incidence rates and efficacy was derived from nilotinib trials. Japanese co\u2010payment maximums were utilized to assess the patient perspective. An estimated 761 and 140 patients were eligible for first\u2010 and second\u2010line nilotinib, respectively, in 2019. Assuming that 100% of eligible patients complied, TFR was associated with cost savings of \u00a57\u00a0625\u00a0174\u00a0640 (US$66\u00a0567\u00a0775) over 3 y. In scenarios with reduced willingness to attempt TFR, cost savings persisted. Achievement of TFR was estimated to markedly reduce out\u2010of\u2010pocket expenses for CML patients, regardless of the timing of relapse. Stopping nilotinib for TFR\u2010eligible patients in Japan may result in significant cost savings to both payers and patients. Monitoring costs contributed little to overall annual costs and decreased over time.<\/jats:p>","DOI":"10.1111\/cas.14430","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T13:15:15Z","timestamp":1587647715000},"page":"2526-2535","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Budget impact analysis of treatment\u2010free remission in nilotinib\u2010treated Japanese chronic myeloid leukemia patients"],"prefix":"10.1111","volume":"111","author":[{"given":"Kiyotaka","family":"Yamazaki","sequence":"first","affiliation":[{"name":"Novartis Pharma K.K. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohito","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Novartis Pharma K.K. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Moldaver","sequence":"additional","affiliation":[{"name":"EVERSANA Burlington ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Viana","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals East Hanover NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1717-6208","authenticated-orcid":false,"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[{"name":"Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine Saga University Saga Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,5,23]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"23","article-title":"Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib","volume":"10","author":"Emole J","year":"2016","journal-title":"Biologics"},{"key":"e_1_2_7_3_1","first-page":"3025","article-title":"Tyrosine kinase inhibitors in Ph+ chronic myeloid leukemia therapy: a review","volume":"17","author":"Shah K","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12659"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S102504"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118820"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201490"},{"key":"e_1_2_7_8_1","first-page":"2589","article-title":"The BCR\u2010ABL tyrosine kinase inhibits apoptosis by activating a Ras\u2010dependent signaling pathway","volume":"13","author":"Cortez D","year":"1996","journal-title":"Oncogene"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2295-0"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4984-3"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70201-7"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-3-47"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-544015"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.102"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-694265"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2914"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00196-9"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.63"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.07.092"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.07.099"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0071"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx219"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2330-1"},{"key":"e_1_2_7_26_1","doi-asserted-by":"crossref","first-page":"A581","DOI":"10.1016\/j.jval.2016.09.1355","article-title":"Modelling the economic impact of implementing treatment\u2010free remission (TFR) in Philadelphia+ (PH+) chronic myelogenous leukemia in chronic phase (CML\u2010CP) patients treated in first line (1l) with the tyrosine kinase inhibitors (TKI): imatinib and nilotinib","volume":"19","author":"Sauvage E","year":"2016","journal-title":"Value Health"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.3293.3293"},{"key":"e_1_2_7_28_1","first-page":"1","article-title":"Budget impact of treatment\u2010free remission in treating chronic\u2010phase Philadelphia\u2010positive chronic myeloid leukemia in Lebanon","volume":"5","author":"Elias F","year":"2019","journal-title":"J Global Oncol"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.270"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.247"},{"key":"e_1_2_7_31_1","unstructured":"America Bo.Foreign Exchange Rates for U.S. Dollars."},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02613-1"},{"issue":"11","key":"e_1_2_7_33_1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1182\/blood.V112.11.186.186","article-title":"International randomized study of interferon versus STI571 (IRIS) 7\u2010year follow\u2010up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM)","volume":"112","author":"O\u2019Brien SG","year":"2008","journal-title":"Blood"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_7_35_1","unstructured":"Ministry of Health Labour and Welfare.2018 Medical Treatment Fee Revision."},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.9123"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903396469"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200725060-00004"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2016.1271337"},{"issue":"40","key":"e_1_2_7_40_1","first-page":"50","article-title":"Molecular monitoring of response in patients with chronic myeloid leukemia","volume":"22","author":"Kolibaba K","year":"2013","journal-title":"Manag Care"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1312377"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000745"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30087-0"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30235-2"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30168-1"},{"key":"e_1_2_7_46_1","unstructured":"Statistics Bureau of Japan. Population Census \u2013 2012\u20132016 Annual Reports."}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcas.14430","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.14430","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cas.14430","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.14430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T04:39:46Z","timestamp":1693888786000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.14430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,23]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1111\/cas.14430"],"URL":"https:\/\/doi.org\/10.1111\/cas.14430","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,23]]},"assertion":[{"value":"2020-01-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}